FAQ Library
![](/content/knowledgecenter/faqlibrary/faqlibrary_2022-08-18_richter_thumb.png)
Dr. Richter describes why personalized medicine is the future of myeloma treatment.
![](/content/knowledgecenter/faqlibrary/faqlibrary_2022-08-16_richter_thumb.png)
Join Dr. Richter as he explains the biggest study from EHA and ASCO 2022 and what it means for patients who are transplant eligible.
![](/content/knowledgecenter/faqlibrary/faqlibrary_2022-08-11_richter_thumb.png)
In this activity, Dr. Richter describes what the current challenges are when managing patients with multiple myeloma.
![](/content/knowledgecenter/faqlibrary/faqlibrary_2022-04-11_usmani_thumb.jpg)
Join Dr. Usmani as he describes how clinicians should monitor patients after their first or second dose after switching from IV daratumumab to subcutaneous.
![](/content/knowledgecenter/faqlibrary/faqlibrary_2022-04-06_lonial_thumb.png)
Dr. Lonial discusses the impact of safety and efficacy in four-drug regimens compared to the three-drug regimens for frontline therapy.
![](/content/knowledgecenter/faqlibrary/faqlibrary_2021-03-23_baljevic2_thumb.png)
In this activity, Dr. Baljevic discusses the side-effect profile associated with four-drug regimens.
![](/content/knowledgecenter/faqlibrary/faqlibrary_2021-03-23_baljevic1_thumb.png)
In this activity, Dr. Baljevic explains the NCCN guidelines outlining four-drug combinations listed for use in newly diagnosed transplant-eligible patients.
![](/content/knowledgecenter/faqlibrary/faqlibrary_2021-01-20_raje_thumb.png)
In this activity, Dr. Raje provides a summary of the KarMMa trial and BB2121 in relapsed/refractory multiple myeloma.
![](/content/knowledgecenter/faqlibrary/faqlibrary_2021-01-14_raje_thumb.png)
Dr. Raje explains therapeutic interventions for smoldering multiple myeloma, as well as how to better risk-stratify patients.
![](/content/knowledgecenter/faqlibrary/faqlibrary_2021-01-12_raje_thumb.png)
In this activity, Dr. Noopur Raje discusses how to risk-stratify patients with smoldering myeloma and the updated definition of symptomatic myeloma.